LEADER 03667nam 2200565 450 001 9910821000603321 005 20200520144314.0 010 $a1-119-06084-2 010 $a1-119-06080-X 010 $a1-119-06072-9 035 $a(CKB)4330000000008245 035 $a(DLC) 2016034128 035 $a(Au-PeEL)EBL4745624 035 $a(CaPaEBR)ebr11300198 035 $a(CaONFJC)MIL978150 035 $a(PPN)196411955 035 $a(MiAaPQ)EBC4745624 035 $a(OCoLC)954037554 035 $a(EXLCZ)994330000000008245 100 $a20160715h20172017 uy| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAntibody-drug conjugates $efundamentals, drug development, and clinical outcomes to target cancer /$fedited by Kenneth J. Olivier Jr. and Sara A. Hurvitz 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons, Incorporated,$d[2017] 210 4$dİ2017 215 $a1 online resource (566 pages) $ccolor illustrations 311 $a1-119-06068-0 320 $aIncludes bibliographical references and index. 327 $aTypical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. 606 $aAntibody-toxin conjugates 606 $aMonoclonal antibodies 606 $aAntineoplastic agents 606 $aTumors$xTreatment 615 0$aAntibody-toxin conjugates. 615 0$aMonoclonal antibodies. 615 0$aAntineoplastic agents. 615 0$aTumors$xTreatment. 676 $a615.7/98 702 $aOlivier$b Kenneth J.$cJr.,$f1968- 702 $aHurvitz$b Sara A.$f1970- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910821000603321 996 $aAntibody-drug conjugates$92231062 997 $aUNINA